Danish pharma giant; diabetes and obesity drugs, global reach
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Anthropic has built a wet lab in the San Francisco Bay Area to accelerate biology work, confirming a shift from in silico research to real-lab experimentation. The move comes amid warnings about AI risks and a looming IPO, with leadership stressing safety while pursuing faster drug development.
Companies are reviewing coverage for GLP-1 weight-loss drugs as costs rise. Some have already trimmed benefits, while others cite long-term employee health benefits as a reason to maintain or adjust coverage. The trend could raise healthcare costs for employers and influence benefits strategies.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.
Anthropic has expanded its biology lab in San Francisco and bought Coefficient Bio to explore AI-assisted biotech. Leaders say real-life lab work is essential to testing AI-driven theories, while the company faces pushback from customers and industry observers over potential competition and safety concerns.
Anthropic has expanded Claude Startup to include more startups, offering up to $45,000 in credits, a $1,000 API credit, and a free year of Claude Team for up to five seats. The initiative, announced during SF Tech Week, aims to accelerate enterprise adoption of Claude and strengthen ties with early-stage companies.
Global demand for frontline AI engineers is surging as firms invest to turn AI models into practical business tools. Salary growth and hiring activity point to a tight talent market, with major tech and consulting firms expanding forward deployed engineering teams to push AI across operations.
The Federal Trade Commission and seven states have asked a federal judge to hold ex-pharma executive Martin Shkreli in contempt for allegedly violating a 2022 lifetime ban by trading pharmaceutical stocks and discussing the industry in livestreams since his release from prison.
OpenAI will integrate Orchestra's team and tech into Rosalind, expanding life-science capabilities; Warp Sciences raises funding to automate wet-lab work and reshore drug development; Orchestra’s acquisition signals AI’s deepening role in pharma, as rivals compete for science-focused platforms.
Anthropic is pitching its Claude models as a catalyst for rapid biological discovery, framing AI as a force to accelerate drug research. Its S-1 highlights life-sciences ambitions and partnerships with pharma giants while Isomorphic Labs is pursuing AI-designed medicines, aiming to design drugs without traditional lab work.
New long-term studies show Wegovy and tirzepatide reduce BMI in children and adolescents, raising hopes for obesity treatment. The FDA now requires warnings about rare eye risk NAION across GLP-1 therapies. Experts caution about long-term effects and equity in access as results signal a potential shift in pediatric care.
The FDA has required makers of GLP‑1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add a warning about a rare eye condition called non‑arteritic anterior ischemic optic neuropathy (NAION). The agency has found a small increased risk in trial and real‑world data and is urging patients with sudden, painless vision loss in one eye to seek prompt ophthalmology evaluation.